Preliminary evidence that hydroxyurea is associated with attenuated peripheral sensitization in adults with sickle cell disease.

Introduction: Hydroxyurea (HU) is a drug that targets the underlying pathophysiology of sickle cell disease (SCD); however, it continues to be an underutilized treatment for adults. Previous research suggests that HU treatment can result in fewer hospital contacts for acute vaso-occlusive pain crises (VOC). Hydroxyurea's impact on non-VOC pain, however, is not well established.

Discrepancies between the medical record and the reports of patients with acute coronary syndrome regarding important aspects of the medical history.

Background: Many critical treatment decisions are based on the medical history of patients with an acute coronary syndrome (ACS). Discrepancies between the medical history documented by a health professional and the patient's own report may therefore have important health consequences.

Methods: Medical histories of 117 patients with an ACS were documented.